Clinical trials: Obinutuzumab
CCND1 Positive, Mantle Cell Lymphoma
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma.
- Conditions
- CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
- Trial name
- NCT03872180
- Testing
- Bendamustine, Obinutuzumab, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Follicular Lymphoma
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal…
- Trial name
- MorningLyte (NCT06284122)
- Testing
- Mosunetuzumab, Lenalidomide, Rituximab
- Where
- 111 sites in Austria, Belgium and 5 more
- Volunteers
- 790 people
- Sponsor
- The Lymphoma Academic Research Organisation
Mantle Cell Lymphoma
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
This study is a multicentric, single arm phase II trial to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by Cisplatinum-Cytarabine-Dexamethasone (DHAP) followed by autologous…
- Trial name
- LyMa101 (NCT02896582)
- Testing
- Obinutuzumab, Dexamethasone, Aracytine
- Where
- 30 sites in France
- Volunteers
- 86 people
- Sponsor
- The Lymphoma Academic Research Organisation
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
Waldenstrom Macroglobulinemia
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
This is a multi-center, single-arm, open label, non-randomized, phase II study designed to investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in patients with relapsed/refractory Waldenström…
- Trial name
- OBI-1 (NCT03679455)
- Testing
- Obinutuzumab 25 MG/ML
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Polish Myeloma Consortium
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Marginal Zone Lymphoma
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
This is a prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab a in untreated marginal zone lymphoma.
- Trial name
- NCT06513234
- Testing
- Orelabrutinib and obinutuzumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia.
- Trial name
- NCT02629809
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Ibrutinib
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib and idelalisib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02968563
- Testing
- Tirabrutinib, Idelalisib, Obinutuzumab
- Where
- 14 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Gilead Sciences
DLBCL - Diffuse Large B Cell Lymphoma
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07326371
- Testing
- Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel
- Volunteers
- 24 people
- Sponsor
- Ruijin Hospital
Lymphoma
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma.
- Trial name
- NCT04464798
- Testing
- CC-220, Rituximab, Obinutuzumab
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- Celgene
Non-Hodgkin Lymphoma, Burkitt Lymphoma
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this…
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- O-ICE (NCT02393157)
- Testing
- Obinutuzumab, Liposomal ARA-C, Ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Leukemia, Lymphocytic, Chronic, B-Cell
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee…
- Trial name
- GLOW (NCT03462719)
- Testing
- Ibrutinib, Venetoclax, Chlorambucil
- Where
- 88 sites in United States, Belgium and 12 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Nephrotic Syndrome，Idiopathic
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
This is a multicenter, open-label, single-arm Phase II clinical trial designed to evaluate the safety, efficacy, and immunological effects of obinutuzumab in adult patients with multi-relapsing, rituximab-dependent…
- Trial name
- OASIS (NCT07233330)
- Testing
- Obinutuzumab
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell…
- Trial name
- TARZAN (NCT06824701)
- Testing
- Zanubrutinib, Rituximab, Obinutuzumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Chronic Lymphocytic Leukemia
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT02100852
- Testing
- TGR-1202 + Obinutuzumab + Chlorambucil
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
This is a multicenter, open-label, single-arm, expanded access treatment study designed to provide obinutuzumab to patients with previously untreated Chronic Lymphocytic Leukemia (CLL) in combination with chlorambucil and to…
- Trial name
- NCT01868893
- Testing
- Obinutuzumab, Chlorambucil
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Diffuse Large B Cell Lymphoma CD20 Positive
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
This study is designed to investigate: the interest of a new monoclonal antibody (GA101)versus rituximab the interest of PET to identify early responders Patients will receive either rituximab (standard treatment), either GA101…
- Trial name
- GAINED (NCT01659099)
- Testing
- GA101, Rituximab, Doxorubicin
- Where
- 122 sites in Belgium, France
- Volunteers
- 671 people
- Sponsor
- The Lymphoma Academic Research Organisation
Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
This investigator-initiated, single-center, single-arm, open-label Phase II study will evaluate the efficacy and safety of sonrotoclax in combination with glofitamab, gemcitabine, and oxaliplatin in adults with relapsed or…
- Trial name
- NCT07774234
- Testing
- Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche